Literature DB >> 11211013

Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials.

R Collins1, S MacMahon.   

Abstract

This two-part review is intended principally for practising clinicians who want to know why some types of evidence about the effects of treatment on survival, and on other major aspects of chronic disease outcome, are much more reliable than others. Although there are a few striking examples of treatments for serious disease which really do work extremely well, most claims for big improvements turn out to be evanescent. Unrealistic expectations about the chances of discovering large treatment effects could misleadingly suggest that evidence from small randomised trials or from non-randomised studies will suffice. By contrast, the reliable assessment of any more moderate effects of treatment on major outcomes--which are usually all that can realistically be expected from most treatments for most common serious conditions--requires studies that guarantee both strict control of bias (which, in general, requires proper randomisation and appropriate analysis, with no unduly data-dependent emphasis on specific parts of the overall evidence) and strict control of random error (which, in general, requires large numbers of deaths or of some other relevant outcome). Past failures to produce such evidence, and to interpret it appropriately, have already led to many premature deaths and much unnecessary suffering.

Entities:  

Mesh:

Year:  2001        PMID: 11211013     DOI: 10.1016/S0140-6736(00)03651-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  86 in total

Review 1.  Prospectively designed overviews of recent trials comparing antihypertensive regimens based on different drug classes.

Authors:  N Chapman; B Neal
Journal:  Curr Hypertens Rep       Date:  2001-08       Impact factor: 5.369

2.  Reduction of postoperative mortality and morbidity. Little information was given on inclusion criteria.

Authors:  T J McCulloch; J A Loadsman
Journal:  BMJ       Date:  2001-05-12

3.  Evaluating treatment effects reliably.

Authors:  Martin J Landray; Gary Whitlock
Journal:  BMJ       Date:  2002-12-14

Review 4.  Clinical endpoints in trials of drugs for cancer: time for a rethink?

Authors:  P P Koopmans
Journal:  BMJ       Date:  2002-06-08

5.  How to spot bias and other potential problems in randomised controlled trials.

Authors:  S C Lewis; C P Warlow
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-02       Impact factor: 10.154

6.  Evidence-based medicine and psychiatric practice.

Authors:  Gregory E Gray; Letitia A Pinson
Journal:  Psychiatr Q       Date:  2003

Review 7.  The challenges of conducting clinical endpoint studies.

Authors:  Jonathan L Isaacsohn; Tiffany A Khodadad; Catherine Soldano-Noble; Jeffrey D Vest
Journal:  Curr Atheroscler Rep       Date:  2003-01       Impact factor: 5.113

8.  Current Status and Future Prospects of Clinical Psychology: Toward a Scientifically Principled Approach to Mental and Behavioral Health Care.

Authors:  Timothy B Baker; Richard M McFall; Varda Shoham
Journal:  Psychol Sci Public Interest       Date:  2008-11-01

9.  CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.

Authors:  David Moher; Sally Hopewell; Kenneth F Schulz; Victor Montori; Peter C Gøtzsche; P J Devereaux; Diana Elbourne; Matthias Egger; Douglas G Altman
Journal:  BMJ       Date:  2010-03-23

Review 10.  Study design issues in evaluating immune biomarkers.

Authors:  Ronald J Bosch; Xinyan Zhang; Netanya G Sandler
Journal:  Curr Opin HIV AIDS       Date:  2013-03       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.